Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus

NCT07801820 · Recruiting

Last updated 2026-09-22

This clinical trial is testing the effects of MWN109 tablets on people with type 2 diabetes to see how it changes their blood sugar levels over 20 weeks compared to a placebo.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 240 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2026-06 · est. completion 2027-03

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07801820 ↗

Description as written by the study sponsor.

This is a randomized, double-blind, placebo- and active-controlled, multicenter Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of MWN109 tablets in participants with type 2 diabetes mellitus (T2DM). Eligible participants will be randomized to receive different dose levels of MWN109 tablets, MWN109-matched placebo, or semaglutide tablets 14 mg (active control), administered once daily for 20 consecutive weeks. Approximately 240 adults aged 18 to 75 years with type 2 diabetes mellitus will be enrolled. The primary endpoint is the percent change from baseline in HbA1c at Week 20. Secondary endpoints include glycemic parameters, body weight, metabolic parameters, adverse events, and immunogenicity.

Treatments tested

MWN109 1 Drug

Administered orally, QD, 20 weeks
MWN109 2 Drug

Administered orally, QD, 20 weeks
MWN109 3 Drug

Administered orally, QD, 20 weeks
MWN109 4 Drug

Administered orally, QD, 20 weeks
Placebo Drug

Administered orally, QD, 20 weeks
Semaglutide Tablets Drug

Administered orally, QD, 20 weeks

Main thing measured	Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 20 Compared to Placebo
Sponsor	Shanghai Minwei Biotechnology Co., Ltd
Conditions studied	Type 2 Diabetes Mellitus (T2DM)
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07801820 ↗